Janux Therapeutics, Inc.
Financials
Valuation Metrics
Janux Therapeutics, Inc.'s Market Cap is $1.06B. At end of 2025 it was $855M. Ranked #2403 of 3,115 in US market (top 77%), #978 of 1,471 on NASDAQ (top 66%), #179 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 68%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.06B | US#2,403/3,115 Sec#179/265 |
| Net Income | $-103M | US—/3,115 Sec—/265 |
| Total Assets | $1.01B | US#2,468/3,115 Sec#102/265 |
| Net Assets | $928M | US#1,807/3,115 Sec#69/265 |
| Employees | 113 | US#2,591/3,115 Sec#166/265 |
| Value | ||
| P/B | 1.15x | US#506/3,115 Sec#25/265 |
| P/S | 106.48x | US#2,950/3,115 Sec#183/265 |
| FCF Yield | -5.12% | US—/3,115 Sec—/265 |
| Profitability | ||
| ROE | -11.06% | US#2,373/3,115 Sec#83/265 |
| ROA | -10.18% | US#2,660/3,115 Sec#103/265 |
| Financial Health | ||
| Debt Ratio | 8.59% | US#85/3,115 Sec#41/265 |
| Total Debt | $21M | US#2,750/3,115 Sec#187/265 |
| FCF | $-55M | US#2,537/3,115 Sec#116/265 |
| Cash | $28M | US#2,776/3,115 Sec#246/265 |
| Current Ratio | 16.35x | US#146/3,115 Sec#40/265 |
| Performance | ||
| 1Y Return | -39.18% | US#2,603/3,115 Sec#209/265 |
| 1M Return | 3.13% | US#1,450/3,115 Sec#76/265 |
| From 52W High | -50.59% | US#2,682/3,115 Sec#208/265 |
| 1Y MDD | -64.94% | US#2,841/3,115 Sec#225/265 |
| Trading | ||
| Volume | 396,040 shares | US#2,262/3,115 Sec#229/265 |
| Trading Value | $7M | US#2,500/3,115 Sec#198/265 |
| Per Share | ||
| EPS | $-1.68 | US—/3,115 Sec—/265 |
| BPS | $15.22 | US#1,510/3,115 Sec#46/265 |
Company Info
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.